Tissue Factor Pathway Inhibitor Reduces Experimental Lung Metastasis of B16 Melanoma^[*]

Summary

The importance of tissue factor (TF) in tumor biology has been highlighted by studies suggesting its involvement in cell signaling, metastasis and angiogenesis. Since many animal studies have shown that anticoagulant therapy can reduce experimental metastasis, we studied whether the natural inhibitor of TF-mediated blood coagulation, Tissue Factor Pathway Inhibitor (TFPI), might be similarly effective. Using a murine experimental model, we found that intravenous injection of recombinant murine TFPI immediately before introduction of tumor cells reduced metastasis by 83% (P <0.001). B16 murine melanoma cells stably transfected with a TFPI expression vector exhibited reduced lung seeding following intravenous injection by 81% (P <0.001) compared with controls. No difference in primary tumor growth was observed between TFPI+ and control cells. Mice receiving intravenous somatic gene transfer of sense TFPI expression vector developed 78% fewer lung nodules than controls (P <0.05). We conclude that TFPI has significant anti-metastatic activity in this experimental model.

Keywords

TFPI - metastasis - melanoma - coagulation - tumor

• References

• 1 Mann K-G, Kalafatis M. The coagulation explosion. Cerebrovasc Dis 1995; 05: 9397.
• 2 Broze Jr G-J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
• 3 Sandset P-M, Abildgaard U. Extrinsic pathway inhibitor – the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39.
• 4 Novotny W-F, Brown S-G, Miletich J-P, Rader D-J, Broze G-J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
• 5 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23: 103-6.
• 6 Lupu C, Poulsen E, Roquefeuil S, Westmuckett A-D, Kakkar V-V, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
• 7 Lupu C, Goodwin CA, Westmuckett AD. et al. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/ caveolae – Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2964-74.
• 8 Lupu C, Lupu F, Dennehy U, Kakkar V-V, Scully M-F. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995; 15: 2055-62.
• 9 Mine S, Yamazaki T, Miyata T, Hara S, Kato H. Structural mechanism of heparin binding of the third Kunitz domain of tissue factor pathway inhibitor. Biochemistry 2002; 41: 78-85.
• 10 Ettelaie C, Adam JM, James NJ. et al. The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor. FEBS Lett 1999; 463: 341-4.
• 11 Francis J-L, Biggerstaff J-P, Amirkhosravi A. Hemostasis and Malignancy. Semin Thromb Hemost 1998; 24: 93-109.
• 12 Rickles F-R, Levine M-N. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28 (Suppl. 03) 43-9.
• 13 Zacharski L-R, Memoli V-A, Costantini V, Wojtukiewicz M-Z, Ornstein D-L. Clotting factors in tumour tissue: implications for cancer therapy. Blood Coagul Fibrinolysis 1990; 01: 71-8.
• 14 Edwards R-L, Morgan D-L, Rickles F-R. Animal tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost 1990; 63: 133-8.
• 15 Edwards R-L, Silver J, Rickles F-R. Human tumor procoagulants: Registry of the Subcommittee of Haemostasis of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 205-13.
• 16 Mueller B-M, Reisfeld R-A, Edgington T-S, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
• 17 Mueller B-M, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-8.
• 18 Rickles F-R, Edwards R-L, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 1983; 51: 301-7.
• 19 Contrino J, Hair G, Kreutzer D-L, Rickles F-R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease [see comments]. Nat Med 1996; 02: 209-15.
• 20 Werling R-W, Zacharski L-R, Kisiel W, Bajaj S-P, Memoli V-A, Rousseau S-M. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
• 21 Chang J-Y, Monroe D-M, Oliver J-A, Liles D-K, Roberts H-R. Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI). Thromb Haemost 1998; 79: 306-9.
• 22 Francis D-A, Francis J-L. Platelet protective anticoagulants improve the reproducibility of the Sonoclot Analyzer. Thromb Haemost 1993; 69: 2161 (Abstract).
• 23 Broze Jr G-J, Miletich J-P. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci U.S.A 1987; 84: 1886-90.
• 24 Hilgard P, Schulte H, Wetzig G, Schmitt G, Schmidt CG. Oral anticoagulation in the treatment of a spontaneously metastasising murine tumor (3LL). Brit J Cancer 1977; 35: 78-85.
• 25 Amirkhosravi M, Francis J-L. Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation. Thromb Haemost 1995; 73: 59-65.
• 26 Wang G, Dong Z, Xu G. et al. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 1998; 124: 615-20.
• 27 Rowe DH, Huang J, Kayton ML. et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms’ tumor. J Pediatr Surg 2000; 35: 30-32.
• 28 Tuszynski G-P. Isolation and characterisation of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem 1987; 262: 9718-23.
• 29 Fischer E-G, Ruf W, Mueller B-M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995; 55: 1629-32.
• 30 Donnelly K-M, Bromberg M-E, Milstone A. et al. M. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb Haemost 1998; 79: 1041-7.
• 31 Falanga A, Bolognese APDalessandro, Casali B, Roncaglioni MC, Donati MB. Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. Int J Cancer 1987; 39: 774-7.